AptarGroup Raises Dividend 4.2% to $0.50, Extends 32-Year Streak

AptarGroup, Inc. raised its quarterly dividend 4.2% to $0.50 from $0.48. ATR shares are due to trade ex-dividend on November 12, 2026, and the payment is scheduled for December 3, 2026. The company posted the dividend announcement with its third-quarter results.

Why the dividend changed

Aptar did not give a separate formula or a single operating trigger for the increase. The board approved the higher payment after a quarter in which reported sales increased 6% and core sales increased 5%. Adjusted earnings per share were $1.52, at the higher end of management’s guidance range, according to the company’s third-quarter results.

New Chief Executive Gael Touya said Aptar’s direction includes deeper customer relationships, faster innovation, more consistent execution and a commitment to “allocate capital thoughtfully.” The dividend increase fits that capital-allocation message. Aptar also said it returned cash through both repurchases and dividends during the quarter, indicating that the higher rate sits within a broader shareholder-return program rather than standing alone.

The operating backdrop was mixed but broadly constructive. All three segments delivered sales growth. Pharma growth was held back by emergency-medicine destocking, although demand remained firm across central nervous system and pulmonary therapies, injectables, consumer healthcare, biologics, vaccines and GLP-1 applications. Beauty benefited from prestige fragrance and color cosmetics, while Closures was helped by beverage and food demand. Margins declined from the prior-year period, and the deconsolidation of Aptar’s Russian subsidiary reduced reported profit. Management nevertheless forecast fourth-quarter adjusted earnings per share of $1.39 to $1.47 and said the emergency-medicine destocking headwind should no longer weigh on Pharma in the fourth quarter.

This was a regular quarterly cash-dividend decision. Aptar disclosed no stock split, spin-off, merger or special distribution tied to the change. The increase therefore reads as a calibrated step supported by underlying operations and management’s stated capital priorities, not a mechanical adjustment for a corporate transaction.

Dividend track record

The payment record shows a stair-step pattern. Aptar paid $0.45 on each of the ex-dividend dates from October 24, 2024, through July 24, 2025. The rate moved to $0.48 for the October 23, 2025, ex-dividend date and remained there for the ex-dividend dates of February 4, May 6 and July 30, 2026. The new $0.50 rate is the next step in that sequence.

Full-year distributions rose from $1.44 in 2020 to $1.50 in 2021, $1.52 in 2022, $1.58 in 2023, $1.72 in 2024 and $1.83 in 2025. The 2025 total was raised 6.4% from the prior year. That progression is consistent with the 4.6% annual growth rate over five years: regular increases, but generally at a measured pace.

Aptar has raised its dividend for 32 consecutive years. The length of that streak matters because it spans multiple business and economic cycles, while the payment history shows that management has tended to preserve the quarterly cadence and move the rate in increments.

Is the dividend covered?

The dividend consumes 34% of earnings. That payout ratio leaves a majority of earnings inside the business for investment, acquisitions, debt service and other capital uses. It also gives earnings room to fluctuate before the dividend would absorb most reported profit.

SmarterDividends rates the dividend A, with a safety score of 95. That falls in the very safe range of 80-100. In plain terms, the grade indicates strong current coverage and a low apparent level of pressure on the payment based on the factors in the safety assessment. It is a measure of present resilience, not a guarantee about future board decisions.

The distinction between reported and underlying results is relevant. Aptar’s third-quarter reported earnings were reduced by the loss associated with deconsolidating its Russian subsidiary, while adjusted earnings landed at the high end of guidance. The 34% earnings payout ratio provides the cleaner reference point for recurring dividend coverage.

Yield and valuation

At a share price of $137.20, Aptar’s forward yield is 1.47%. That is below the Healthcare sector median forward yield of 1.69%. The comparison places ATR below the sector’s midpoint for current income, even after the latest rate increase.

SmarterDividends estimates fair value at $109.84 and classifies the shares as overvalued, with 20% downside to that estimate. The stock also carries a 10.0% one-year price gain. Those figures explain why the yield remains below the sector median: the income stream is being measured against a share price above the fair-value estimate.

What to watch

The immediate calendar item is November 12, 2026, the next ex-dividend date. The payment is due December 3, 2026. Investors tracking eligibility and cash receipt need to distinguish those two dates.

Operationally, the next test is Aptar’s fourth-quarter performance against management’s adjusted earnings guidance of $1.39 to $1.47 per share. Pharma demand without the emergency-medicine destocking headwind, progress in Beauty’s North American operations and continued beverage momentum in Closures are the specific items management identified in its latest outlook.

Capital allocation also bears watching under Touya, who began his CEO tenure during 2026. The company paired the dividend increase with continued repurchases and emphasized disciplined allocation. Future earnings releases will provide evidence of how Aptar balances dividends, buybacks, acquisitions and investment while maintaining the 34% earnings payout ratio and its 32-year dividend-growth streak.